Understanding Why Halozyme Therapeutics Stock Is Moving Up Today.

Halozyme Therapeutics stock is trading -27.98% below its average target price of $50.3 after marking a 5.2% during today's afternoon session. Analysts are giving the mid-cap Biotechnology company an average rating of buy and target prices ranging from $28.0 to $72.0 per share.

Halozyme Therapeutics has an average level of shares sold short, at 6.6% of its total share float. The stock's short ratio (also called days to cover) is 6.83. Only 1.0% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders.

Institutional investors own 95.1% of Halozyme Therapeutics's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Halozyme Therapeutics

Date Reported Holder Percentage Shares Value
2023-09-30 Blackrock Inc. 14% 18,118,615 $656,346,800
2023-09-30 Vanguard Group Inc 10% 13,106,644 $474,788,158
2023-09-30 Artisan Partners Limited Partnership 6% 7,712,874 $279,398,848
2023-09-30 State Street Corporation 5% 6,209,531 $224,940,251
2023-09-30 Snyder Capital Management, LP 3% 4,324,232 $156,645,297
2023-09-30 Macquarie Group Limited 3% 3,444,190 $124,765,777
2023-09-30 Alliancebernstein L.P. 3% 3,356,776 $121,599,205
2023-09-30 JP Morgan Chase & Company 2% 3,163,265 $114,589,269
2023-09-30 Geode Capital Management, LLC 2% 2,787,349 $100,971,713
2023-09-30 Marshall Wace LLP 2% 2,724,811 $98,706,274
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.